HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dermatomyositis induced by drug therapy: a review of case reports.

AbstractBACKGROUND:
Drugs have occasionally been implicated in dermatomyositis (DM) onset.
OBJECTIVE:
We sought to review case reports of drug-induced DM.
METHODS:
Articles were gathered from MEDLINE and bibliographies of acquired reports. Causality was assessed using World Health Organization criteria. Clinical characteristics, management, and resolution were examined.
RESULTS:
In 70 reported cases, 50% of patients were female and the median age was 57 years. Hydroxyurea was implicated in 51% of cases. All cases had pathognomonic (76%) or compatible (24%) cutaneous findings. Hydroxyurea cases lacked myositis, but myositis was described in 79.4% of nonhydroxyurea cases. Drug causality was probable (25.7%) or possible (74.3%), but not certain in any case. Most patients had underlying pathology associated with DM (44% had malignancy; 16% had rheumatoid arthritis). Of the sample, 84.3% had improvement of DM after discontinuation of the drug.
LIMITATIONS:
Case reports may emphasize unusual findings.
CONCLUSIONS:
Further work is needed to differentiate drug effects from underlying, predisposing factors.
AuthorsAnne M Seidler, Alice B Gottlieb
JournalJournal of the American Academy of Dermatology (J Am Acad Dermatol) Vol. 59 Issue 5 Pg. 872-80 (Nov 2008) ISSN: 1097-6787 [Electronic] United States
PMID18625537 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't, Review)
Chemical References
  • Antibodies, Antinuclear
  • Etoposide
  • Cyclophosphamide
  • Hydroxyurea
Topics
  • Adult
  • Aged
  • Antibodies, Antinuclear (analysis)
  • Autoimmune Diseases (drug therapy)
  • Cyclophosphamide (adverse effects)
  • Dermatomyositis (chemically induced, pathology)
  • Etoposide (adverse effects)
  • Female
  • Humans
  • Hydroxyurea (adverse effects)
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive (complications, drug therapy)
  • Male
  • Middle Aged
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma (drug therapy)
  • Skin (pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: